{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:41:01Z","timestamp":1789569661499,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Fujian Provincial Science and Technology Innovation Joint Fund Project","award":["2023Y9110"],"award-info":[{"award-number":["2023Y9110"]}]},{"name":"the Fujian Provincial Health Technology Project","award":["2022CXA020"],"award-info":[{"award-number":["2022CXA020"]}]},{"name":"the Natural Science Foundation of Fujian Province","award":["2021J01720"],"award-info":[{"award-number":["2021J01720"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02267-y","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:54:42Z","timestamp":1774716882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["[68Ga]Ga-labeled fibroblast activation protein inhibitor PET\/CT for monitoring neoadjuvant chemotherapy responses in breast cancer subtypes"],"prefix":"10.1186","volume":"28","author":[{"given":"Ling","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunwang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-7964","authenticated-orcid":false,"given":"Youzhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"2267_CR1","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/s0140-6736(11)61539-0","volume":"378","author":"JS Reis-Filho","year":"2011","unstructured":"Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378:1812\u201323. https:\/\/doi.org\/10.1016\/s0140-6736(11)61539-0.","journal-title":"Lancet"},{"key":"2267_CR2","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1200\/jco.2008.18.1024","volume":"27","author":"J Hugh","year":"2009","unstructured":"Hugh J, Hanson J, Cheang MCU, Nielsen TO, Perou CM, Dumontet C, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168\u201376. https:\/\/doi.org\/10.1200\/jco.2008.18.1024.","journal-title":"J Clin Oncol"},{"key":"2267_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1158\/1078-0432.ccr-15-0757","volume":"22","author":"M Callari","year":"2016","unstructured":"Callari M, Cappelletti V, D\u2019Aiuto F, Musella V, Lembo A, Petel F, et al. Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer. Clin Cancer Res. 2016;22:337\u201345. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-0757.","journal-title":"Clin Cancer Res"},{"key":"2267_CR4","doi-asserted-by":"publisher","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe J-M, Smidt ML, et al. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease. JAMA Surg. 2021;156:e210891. https:\/\/doi.org\/10.1001\/jamasurg.2021.0891.","journal-title":"JAMA Surg"},{"key":"2267_CR5","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/nejmoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147\u201359. https:\/\/doi.org\/10.1056\/nejmoa1612645.","journal-title":"N Engl J Med"},{"key":"2267_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/nejmoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u201328. https:\/\/doi.org\/10.1056\/nejmoa1814017.","journal-title":"N Engl J Med"},{"key":"2267_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77\u201390. https:\/\/doi.org\/10.1016\/s1470-2045(22)00694-5.","journal-title":"Lancet Oncol"},{"key":"2267_CR8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/jnci\/djn085","volume":"100","author":"G von Minckwitz","year":"2008","unstructured":"von Minckwitz G, K\u00fcmmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100:542\u201351. https:\/\/doi.org\/10.1093\/jnci\/djn085.","journal-title":"J Natl Cancer Inst"},{"key":"2267_CR9","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.1200\/jco.2006.05.7406","volume":"24","author":"C Rousseau","year":"2006","unstructured":"Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366\u201372. https:\/\/doi.org\/10.1200\/jco.2006.05.7406.","journal-title":"J Clin Oncol"},{"key":"2267_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00259-010-1660-5","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux D, Giacchetti S, Espie M, Rubello D, Moretti J, Hindi\u00e9 E. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET\/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging. 2011;38:419\u201325. https:\/\/doi.org\/10.1007\/s00259-010-1660-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2267_CR11","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.ejca.2013.07.151","volume":"49","author":"S Sanz-Viedma","year":"2013","unstructured":"Sanz-Viedma S, Sanchez-Mu\u00f1oz A, Scholz-Gutierrez V, Jimenez-Hoyuela JM, Alavi A, Alba E. 18F-FDG-PET\/CT in predicting pathologic complete response after neoadjuvant chemotherapy: the early metabolic response is the answer. Eur J Cancer. 2013;49:3573\u20134. https:\/\/doi.org\/10.1016\/j.ejca.2013.07.151.","journal-title":"Eur J Cancer"},{"key":"2267_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.breast.2012.12.020","volume":"22","author":"BB Koolen","year":"2013","unstructured":"Koolen BB, Pengel KE, Wesseling J, Vogel WV, Peeters M-JTFDV, Vincent AD, et al. FDG PET\/CT during neoadjuvant chemotherapy may predict response in ER-positive\/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast. 2013;22:691\u20137. https:\/\/doi.org\/10.1016\/j.breast.2012.12.020.","journal-title":"Breast"},{"key":"2267_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1148\/radiol.2015141638","volume":"277","author":"D Groheux","year":"2015","unstructured":"Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindi\u00e9 E, Giacchetti S, et al. Early metabolic response to neoadjuvant treatment: FDG PET\/CT criteria according to breast cancer subtype. Radiology. 2015;277:358\u201371. https:\/\/doi.org\/10.1148\/radiol.2015141638.","journal-title":"Radiology"},{"key":"2267_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/rlu.0000000000002348","volume":"44","author":"H Lee","year":"2019","unstructured":"Lee H, Lee D, Park S, Kim TS, Jung S-Y, Lee S, et al. Predicting response to neoadjuvant chemotherapy in patients with breast cancer: combined statistical modeling using clinicopathological factors and FDG PET\/CT texture parameters. Clin Nucl Med. 2019;44:21\u20139. https:\/\/doi.org\/10.1097\/rlu.0000000000002348.","journal-title":"Clin Nucl Med"},{"key":"2267_CR15","doi-asserted-by":"publisher","first-page":"e13062","DOI":"10.1200\/jco.2010.28.15_suppl.e13062","volume":"28","author":"S Bauer","year":"2010","unstructured":"Bauer S, Fischer E, Wuest T, Scott AM, Schibli R, Ritter G, et al. Antibody targeting of epithelial carcinoma-associated fibroblast activation protein blocks cellular proliferation, migration, and invasion. J Clin Oncol. 2010;28:e13062\u201313062. https:\/\/doi.org\/10.1200\/jco.2010.28.15_suppl.e13062.","journal-title":"J Clin Oncol"},{"key":"2267_CR16","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s12149-021-01616-5","volume":"35","author":"H K\u00f6mek","year":"2021","unstructured":"K\u00f6mek H, Can C, G\u00fczel Y, Oru\u00e7 Z, G\u00fcndo\u011fan C, Yildirim \u00d6A, et al. 68Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET\/CT. Ann Nucl Med. 2021;35:744\u201352. https:\/\/doi.org\/10.1007\/s12149-021-01616-5.","journal-title":"Ann Nucl Med"},{"key":"2267_CR17","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s12149-021-01672-x","volume":"35","author":"U Elboga","year":"2021","unstructured":"Elboga U, Sahin E, Kus T, Cayirli YB, Aktas G, Uzun E, et al. Superiority of 68Ga-FAPI PET\/CT scan in detecting additional lesions compared to 18FDG PET\/CT scan in breast cancer. Ann Nucl Med. 2021;35:1321\u201331. https:\/\/doi.org\/10.1007\/s12149-021-01672-x.","journal-title":"Ann Nucl Med"},{"key":"2267_CR18","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1097\/rlu.0000000000004523","volume":"48","author":"S Zheng","year":"2023","unstructured":"Zheng S, Lin J, Zhu Y, Chen Y, Zhang J, Chen X, et al. 68Ga-FAPI versus 18F-FDG PET\/CT in evaluating newly diagnosed breast cancer patients: a head-to-head comparative study. Clin Nucl Med. 2023;48:e104\u20139. https:\/\/doi.org\/10.1097\/rlu.0000000000004523.","journal-title":"Clin Nucl Med"},{"key":"2267_CR19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3390\/cancers15030908","volume":"15","author":"S Taralli","year":"2023","unstructured":"Taralli S, Lorusso M, Perrone E, Perotti G, Zagaria L, Calcagni ML. PET\/CT with fibroblast activation protein inhibitors in breast cancer: diagnostic and theranostic application\u2014a literature review. Cancers. 2023;15:908. https:\/\/doi.org\/10.3390\/cancers15030908.","journal-title":"Cancers"},{"key":"2267_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2967\/jnumed.122.264871","volume":"64","author":"P Backhaus","year":"2022","unstructured":"Backhaus P, Burg MC, Asmus I, Pixberg M, B\u00fcther F, Breyholz H-J, et al. Initial results of 68Ga-FAPI-46 PET\/MRI to assess response to neoadjuvant chemotherapy in breast cancer. J Nucl Med: Off Publ Soc Nucl Med. 2022;64:717\u201323. https:\/\/doi.org\/10.2967\/jnumed.122.264871.","journal-title":"J Nucl Med: Off Publ Soc Nucl Med"},{"key":"2267_CR21","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2967\/jnumed.123.266079","volume":"64","author":"L Chen","year":"2023","unstructured":"Chen L, Zheng S, Chen L, Xu S, Wu K, Kong L, et al. 68Ga-labeled fibroblast activation protein inhibitor PET\/CT for the early and late prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients: a prospective study. J Nucl Med. 2023;64:1899\u2013905.","journal-title":"J Nucl Med"},{"key":"2267_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00259-025-07597-1","volume":"53","author":"NA Selcuk","year":"2025","unstructured":"Selcuk NA, Beydagi G, Akcay K, Gormez A, Toklu T, Kabasakal L The role of [68Ga]Ga-FAP-2286 PET\/CT in the evaluation of treatment response in gastrointestinal system malignancies. Eur J Nucl Med Mol Imaging. 2025;53:1\u20137. https:\/\/doi.org\/10.1007\/s00259-025-07597-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2267_CR23","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1038\/s41467-022-32782-3","volume":"13","author":"EI Rivas","year":"2022","unstructured":"Rivas EI, Linares J, Zwick M, G\u00f3mez-Llonin A, Guiu M, Labernadie A, et al. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+\u2009breast tumors. Nat Commun. 2022;13:5310. https:\/\/doi.org\/10.1038\/s41467-022-32782-3.","journal-title":"Nat Commun"},{"key":"2267_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00054-0","author":"JM P\u00e9rez-Garc\u00eda","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda JM, Cort\u00e9s J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024. https:\/\/doi.org\/10.1016\/s0140-6736(24)00054-0.","journal-title":"Lancet"},{"key":"2267_CR25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-2498","author":"Z Shi","year":"2021","unstructured":"Shi Z, Wulfkuhle J, Nowicka M, Gallagher RI, Saura C, Nuciforo PG, et al. Functional mapping of AKT signaling and biomarkers of response from the fairlane trial of neoadjuvant ipatasertib plus paclitaxel for triple-negative breast cancer. Clin Cancer Res. 2021. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-2498","journal-title":"Clin Cancer Res"},{"key":"2267_CR26","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells12081182","volume":"12","author":"R Vishnubalaji","year":"2023","unstructured":"Vishnubalaji R, Alajez NM. Single-cell transcriptome analysis revealed heterogeneity and identified novel therapeutic targets for breast cancer subtypes. Cells. 2023;12:1182. https:\/\/doi.org\/10.3390\/cells12081182.","journal-title":"Cells"},{"key":"2267_CR27","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41416-020-01226-4","volume":"124","author":"RV Broad","year":"2021","unstructured":"Broad RV, Jones SJ, Teske MC, Wastall LM, Hanby AM, Thorne JL, et al. Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy. Br J Cancer. 2021;124:1110\u201320. https:\/\/doi.org\/10.1038\/s41416-020-01226-4.","journal-title":"Br J Cancer"},{"key":"2267_CR28","doi-asserted-by":"publisher","first-page":"103460","DOI":"10.1016\/j.ebiom.2021.103460","volume":"69","author":"Y Yu","year":"2021","unstructured":"Yu Y, He Z, Ouyang J, Tan Y, Chen Y, Gu Y, et al. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: a machine learning, multicenter study. EBioMedicine. 2021;69:103460. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103460.","journal-title":"EBioMedicine"},{"key":"2267_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06873-w","author":"T Liu","year":"2024","unstructured":"Liu T, Xu S, Cheng K, Pei J, Wang S, Li C, et al Exploring the value of FAP-targeted PET\/CT in differentiating breast cancer molecular subtypes: a preliminary study. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06873-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2267_CR30","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50:1906\u201318. https:\/\/doi.org\/10.1007\/s00259-023-06144-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2267_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11547-025-01958-4","volume":"130","author":"L Urso","year":"2025","unstructured":"Urso L, Manco L, Cittanti C, Adamantiadis S, Szilagyi KE, Scribano G, et al. 18F-FDG PET\/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Radiol Med. 2025;130:543\u201354. https:\/\/doi.org\/10.1007\/s11547-025-01958-4.","journal-title":"Radiol Med"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02267-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:48:16Z","timestamp":1778122096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02267-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2267"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02267-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7923854\/v1","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University (Date: [January 10, 2020]\/No. MRCTA, ECFAH of FMU [2019] 293). The study was prospectively registered at ClinicalTrials.gov (NCT04499365) on August 5, 2020. Written informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of the data and any accompanying images in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}